LLY

991.77

-0.04%↓

JNJ

223.54

-1.04%↓

ABBV

204.37

-0.91%↓

UNH

367.44

+1.19%↑

AZN

184.35

+1.72%↑

LLY

991.77

-0.04%↓

JNJ

223.54

-1.04%↓

ABBV

204.37

-0.91%↓

UNH

367.44

+1.19%↑

AZN

184.35

+1.72%↑

LLY

991.77

-0.04%↓

JNJ

223.54

-1.04%↓

ABBV

204.37

-0.91%↓

UNH

367.44

+1.19%↑

AZN

184.35

+1.72%↑

LLY

991.77

-0.04%↓

JNJ

223.54

-1.04%↓

ABBV

204.37

-0.91%↓

UNH

367.44

+1.19%↑

AZN

184.35

+1.72%↑

LLY

991.77

-0.04%↓

JNJ

223.54

-1.04%↓

ABBV

204.37

-0.91%↓

UNH

367.44

+1.19%↑

AZN

184.35

+1.72%↑

Home・Lista de Ações・Incyte Corp

Incyte Corp

Abrir

SetorSaúde

99.16 2.6

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

96.73

Máximo

99.46

Indicadores-chave
By Trading Economics
Rendimento	4.1M 303M
Vendas	-234M 1.3B
P/E Médio do Setor	13.682 49.8
EPS	1.81
Margem de lucro	23.834
Funcionários	2,844
EBITDA	-47M 367M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+11.24% upside

Dividendos
By Dow Jones
Próximos Ganhos	28 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	358M 19B
Abertura anterior	96.56
Fecho anterior	99.16

Sentimento de Notícias

By Acuity

25%

75%

92 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

59.52 / 62.66 Suporte e Resistência

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de mai. de 2026, 23:43 UTC

Notícias Principais

New Zealand's Unemployment Rate Falls in 1Q

5 de mai. de 2026, 23:20 UTC

Ações em Alta

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 de mai. de 2026, 21:48 UTC

Ganhos

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 de mai. de 2026, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 de mai. de 2026, 00:00 UTC

Conversa de Mercado

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 de mai. de 2026, 22:26 UTC

Conversa de Mercado

AMD Data-Center Business Continues to Surge -- Market Talk

5 de mai. de 2026, 22:20 UTC

Conversa de Mercado

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 de mai. de 2026, 22:08 UTC

Ganhos

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 de mai. de 2026, 22:07 UTC

Ganhos

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:48 UTC

Ganhos

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 de mai. de 2026, 21:48 UTC

Ganhos

Pan American Silver 1Q Rev $1.2B >PAAS

5 de mai. de 2026, 21:42 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:38 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:30 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:29 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:26 UTC

Ganhos

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 de mai. de 2026, 21:25 UTC

Ganhos

Alcon Inc. 1Q EPS 39c >ALC.EB

5 de mai. de 2026, 21:25 UTC

Ganhos

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 de mai. de 2026, 21:24 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:18 UTC

Ganhos

Mistras Backs 2026 Rev $730M-$750M >MG

5 de mai. de 2026, 21:17 UTC

Ganhos

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 de mai. de 2026, 21:15 UTC

Ganhos

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 de mai. de 2026, 21:12 UTC

Ganhos

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 de mai. de 2026, 21:11 UTC

Ganhos

SSR Mining 1Q Rev $581.8M >SSRM

5 de mai. de 2026, 21:10 UTC

Ganhos

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 de mai. de 2026, 21:10 UTC

Ganhos

SSR Mining 1Q EPS $1.16 >SSRM

5 de mai. de 2026, 21:08 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:01 UTC

Ganhos

Intact Financial 1Q EPS C$4.12 >IFC.T

5 de mai. de 2026, 21:01 UTC

Ações em Alta

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

11.24% parte superior

Previsão para 12 meses

Média 108.06 USD 11.24%

Máximo 135 USD

Mínimo 75 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

19 ratings

Comprar

Manter

Vender

Com base em 19 analistas que deram avaliações de ações para Incyte Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

59.52 / 62.66Suporte e Resistência

Bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

92 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation